unlearn.ai
AI platform creating digital twins of patients to optimize, shorten, and de-risk clinical trials.
What is unlearn.ai?
Unlearn.ai is a clinical research platform that leverages artificial intelligence to create highly precise digital twins of clinical trial participants. The Unlearn platform operates an advanced machine learning engine known as a Boltzmann machine (specifically a Conditional Restricted Boltzmann Machine) to generate comprehensive, personalized clinical trial digital twin trajectories. By computing what would happen if a specific patient received a placebo, the platform introduces TwinRCTs, which utilize their proprietary PROCOVA (Prognostic Covariate Adjustment) statistical methodology. Backed by research papers and a positive qualification opinion from the EMA alongside alignment with US FDA guidance, Unlearn helps global pharmaceutical groups like Johnson & Johnson design smaller, faster, and more powerful randomized controlled trials across complex medical areas like Alzheimer's and ALS.
Category
Best unlearn.ai use cases by task, role, industry, and platform
These use cases show where unlearn.ai fits best, ranked by fit score before popularity or pricing.
unlearn.ai Pricing Plans
Compare unlearn.ai free options, unlearn.ai paid pricing plans, and usage notes before you choose the best way to use this AI tool in 2026.
Contact for Pricing
Pricing updated:Jun 12, 2026
unlearn.ai AI Features
unlearn.ai Pros and Cons
Pros
- Significantly reduces patient enrollment bottlenecks and associated millions in trial costs
- Saves up to several months in clinical trial enrollment times
- Fully qualified by the EMA and explicitly aligned with current FDA guidance
- Minimizes the ethical burden of exposing real human participants to placebos
Limitations
- Requires large volumes of clean, harmonized historical patient data to train reliable disease models
- May have reduced predictive accuracy if standard-of-care treatments change dramatically over time
- Primarily optimized for continuous, slowly progressing indications like neuroscience (Alzheimer's, ALS) and metabolic diseases